Progress in the detection and treatment of cancer has led to an impressive reduction in both
mortality and morbidity. Due to their mechanism of action, however, conventional …

Angiogenesis—one of the hallmarks of cancer—has emerged as a valid therapeutic target in
oncology. The VEGF system represents a key mediator of tumor-initiated angiogenesis and …

Background Results of two phase 3 trials have shown first-line bevacizumab in combination
with chemotherapy improves clinical outcomes in patients with advanced or recurrent non …

The use of anti-angiogenic agents as part of the therapeutic armamentarium for advanced
stage solid tumors has become the standard of care in several instances, particularly for …

The development of tyrosine kinase inhibitors (TKI) represents a major milestone in
oncology. However, their use has been found to be associated with serious toxicities that …

Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiological entity that
may occur in patients receiving anti-vascular endothelial growth factor (VEGF) agents such …

Neurological complications of cancer and of anticancer treatments can be substantially
disabling to patients, especially with classic chemotherapies. As a rare but important …

Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation
Trial in Patients With Renal Cell C Page 1 Antitumor Activity and Safety of Tivozanib (AV-951) …

The advent of targeted anticancer therapies over the past few decades has reinvigorated the
field of cancer therapeutics, with the promise of increased cancer cure rates accompanied …

Central nervous system (CNS) metastasis from breast cancer may be characterized as either
parenchymal brain metastasis (BM) or leptomeningeal (LM) metastasis. BM are much more …